Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial. (nature.com)

Authors: Klem L … Kjolby M Journal: Nature Communications Published: 2026-09-14 DOI: https://doi.org/10.1038/s41467-026-77638-2